17-02-2022
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Read all
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025
02-12-2021
Kedrion Biopharma to commercialize RYPLAZIM® in U.S
Read all
RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1
18-10-2021
Kedrion grows in North America as it completes acquisition of Prometic
Read all
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency